Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity

Carlo Toniatti, Andrea Cabibbo, Elisabetta Sporeno, Anna Laura Salvati, Mauro Cerretani, Sergio Serafini, Armin Lahm, Riccardo Cortese, Gennaro Ciliberto

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Interleukin-6 (IL-6) triggers the formation of a high affinity receptor complex with the ligand binding subunit IL-6Rα and the signal transducing chain gp130. Since the intracytoplasmic region of the IL-6Rα does not contribute to signaling, soluble forms of the extracytoplasmic domain (sIL-6Rα), potentiate IL-6 bioactivity and induce a cytokine-responsive status in cells expressing gp130 only. This observation, together with the detection of high levels of circulating soluble human IL-6Rα (shIL-6Rα) in sera, suggests that the hIL-6-shIL-6Rα complex is an alternative form of the cytokine. Here we describe the generation of human IL-6 (hIL-6) variants with strongly enhanced shIL-6Rα binding activity and bioactivity. Homology modeling and site-directed mutagenesis of hIL-6 suggested that the binding interface for hIL-6Rα is constituted by the C-terminal portion of the D-helix and residues contained in the AB loop. Four libraries of hIL-6 mutants were generated by each time fully randomizing four different amino acids in the predicted AB loop. These libraries were displayed monovalently on filamentous phage surface and sorted separately for binding to immobilized shIL-6Rα. Mutants were selected which, when expressed as soluble proteins, showed a 10- to 40-fold improvement in shIL-6Rα binding; a further increase (up to 70-fold) was achieved by combining variants isolated from different libraries. Interestingly, high affinity hIL-6 variants show strongly enhanced bioactivity on cells expressing gp130 in the presence of shIL-6Rα at concentrations similar to those normally found in human sera.

Original languageEnglish
Pages (from-to)2726-2737
Number of pages12
JournalEMBO Journal
Volume15
Issue number11
Publication statusPublished - 1996

Fingerprint

Human Engineering
Human engineering
Bioactivity
Interleukin-6
Libraries
Cells
Cytokines
Mutagenesis
Bacteriophages
Ligands
Amino Acids
Site-Directed Mutagenesis
Serum

Keywords

  • BAF cells
  • IL-6
  • IL-6 receptor superagonists
  • IL-6R
  • Phage display

ASJC Scopus subject areas

  • Genetics
  • Cell Biology

Cite this

Toniatti, C., Cabibbo, A., Sporeno, E., Salvati, A. L., Cerretani, M., Serafini, S., ... Ciliberto, G. (1996). Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity. EMBO Journal, 15(11), 2726-2737.

Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity. / Toniatti, Carlo; Cabibbo, Andrea; Sporeno, Elisabetta; Salvati, Anna Laura; Cerretani, Mauro; Serafini, Sergio; Lahm, Armin; Cortese, Riccardo; Ciliberto, Gennaro.

In: EMBO Journal, Vol. 15, No. 11, 1996, p. 2726-2737.

Research output: Contribution to journalArticle

Toniatti, C, Cabibbo, A, Sporeno, E, Salvati, AL, Cerretani, M, Serafini, S, Lahm, A, Cortese, R & Ciliberto, G 1996, 'Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity', EMBO Journal, vol. 15, no. 11, pp. 2726-2737.
Toniatti C, Cabibbo A, Sporeno E, Salvati AL, Cerretani M, Serafini S et al. Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity. EMBO Journal. 1996;15(11):2726-2737.
Toniatti, Carlo ; Cabibbo, Andrea ; Sporeno, Elisabetta ; Salvati, Anna Laura ; Cerretani, Mauro ; Serafini, Sergio ; Lahm, Armin ; Cortese, Riccardo ; Ciliberto, Gennaro. / Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity. In: EMBO Journal. 1996 ; Vol. 15, No. 11. pp. 2726-2737.
@article{5ecdbdd48add4e3ba40f2c0179a81b1b,
title = "Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity",
abstract = "Interleukin-6 (IL-6) triggers the formation of a high affinity receptor complex with the ligand binding subunit IL-6Rα and the signal transducing chain gp130. Since the intracytoplasmic region of the IL-6Rα does not contribute to signaling, soluble forms of the extracytoplasmic domain (sIL-6Rα), potentiate IL-6 bioactivity and induce a cytokine-responsive status in cells expressing gp130 only. This observation, together with the detection of high levels of circulating soluble human IL-6Rα (shIL-6Rα) in sera, suggests that the hIL-6-shIL-6Rα complex is an alternative form of the cytokine. Here we describe the generation of human IL-6 (hIL-6) variants with strongly enhanced shIL-6Rα binding activity and bioactivity. Homology modeling and site-directed mutagenesis of hIL-6 suggested that the binding interface for hIL-6Rα is constituted by the C-terminal portion of the D-helix and residues contained in the AB loop. Four libraries of hIL-6 mutants were generated by each time fully randomizing four different amino acids in the predicted AB loop. These libraries were displayed monovalently on filamentous phage surface and sorted separately for binding to immobilized shIL-6Rα. Mutants were selected which, when expressed as soluble proteins, showed a 10- to 40-fold improvement in shIL-6Rα binding; a further increase (up to 70-fold) was achieved by combining variants isolated from different libraries. Interestingly, high affinity hIL-6 variants show strongly enhanced bioactivity on cells expressing gp130 in the presence of shIL-6Rα at concentrations similar to those normally found in human sera.",
keywords = "BAF cells, IL-6, IL-6 receptor superagonists, IL-6R, Phage display",
author = "Carlo Toniatti and Andrea Cabibbo and Elisabetta Sporeno and Salvati, {Anna Laura} and Mauro Cerretani and Sergio Serafini and Armin Lahm and Riccardo Cortese and Gennaro Ciliberto",
year = "1996",
language = "English",
volume = "15",
pages = "2726--2737",
journal = "EMBO Journal",
issn = "0261-4189",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity

AU - Toniatti, Carlo

AU - Cabibbo, Andrea

AU - Sporeno, Elisabetta

AU - Salvati, Anna Laura

AU - Cerretani, Mauro

AU - Serafini, Sergio

AU - Lahm, Armin

AU - Cortese, Riccardo

AU - Ciliberto, Gennaro

PY - 1996

Y1 - 1996

N2 - Interleukin-6 (IL-6) triggers the formation of a high affinity receptor complex with the ligand binding subunit IL-6Rα and the signal transducing chain gp130. Since the intracytoplasmic region of the IL-6Rα does not contribute to signaling, soluble forms of the extracytoplasmic domain (sIL-6Rα), potentiate IL-6 bioactivity and induce a cytokine-responsive status in cells expressing gp130 only. This observation, together with the detection of high levels of circulating soluble human IL-6Rα (shIL-6Rα) in sera, suggests that the hIL-6-shIL-6Rα complex is an alternative form of the cytokine. Here we describe the generation of human IL-6 (hIL-6) variants with strongly enhanced shIL-6Rα binding activity and bioactivity. Homology modeling and site-directed mutagenesis of hIL-6 suggested that the binding interface for hIL-6Rα is constituted by the C-terminal portion of the D-helix and residues contained in the AB loop. Four libraries of hIL-6 mutants were generated by each time fully randomizing four different amino acids in the predicted AB loop. These libraries were displayed monovalently on filamentous phage surface and sorted separately for binding to immobilized shIL-6Rα. Mutants were selected which, when expressed as soluble proteins, showed a 10- to 40-fold improvement in shIL-6Rα binding; a further increase (up to 70-fold) was achieved by combining variants isolated from different libraries. Interestingly, high affinity hIL-6 variants show strongly enhanced bioactivity on cells expressing gp130 in the presence of shIL-6Rα at concentrations similar to those normally found in human sera.

AB - Interleukin-6 (IL-6) triggers the formation of a high affinity receptor complex with the ligand binding subunit IL-6Rα and the signal transducing chain gp130. Since the intracytoplasmic region of the IL-6Rα does not contribute to signaling, soluble forms of the extracytoplasmic domain (sIL-6Rα), potentiate IL-6 bioactivity and induce a cytokine-responsive status in cells expressing gp130 only. This observation, together with the detection of high levels of circulating soluble human IL-6Rα (shIL-6Rα) in sera, suggests that the hIL-6-shIL-6Rα complex is an alternative form of the cytokine. Here we describe the generation of human IL-6 (hIL-6) variants with strongly enhanced shIL-6Rα binding activity and bioactivity. Homology modeling and site-directed mutagenesis of hIL-6 suggested that the binding interface for hIL-6Rα is constituted by the C-terminal portion of the D-helix and residues contained in the AB loop. Four libraries of hIL-6 mutants were generated by each time fully randomizing four different amino acids in the predicted AB loop. These libraries were displayed monovalently on filamentous phage surface and sorted separately for binding to immobilized shIL-6Rα. Mutants were selected which, when expressed as soluble proteins, showed a 10- to 40-fold improvement in shIL-6Rα binding; a further increase (up to 70-fold) was achieved by combining variants isolated from different libraries. Interestingly, high affinity hIL-6 variants show strongly enhanced bioactivity on cells expressing gp130 in the presence of shIL-6Rα at concentrations similar to those normally found in human sera.

KW - BAF cells

KW - IL-6

KW - IL-6 receptor superagonists

KW - IL-6R

KW - Phage display

UR - http://www.scopus.com/inward/record.url?scp=0029931316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029931316&partnerID=8YFLogxK

M3 - Article

C2 - 8654370

AN - SCOPUS:0029931316

VL - 15

SP - 2726

EP - 2737

JO - EMBO Journal

JF - EMBO Journal

SN - 0261-4189

IS - 11

ER -